Moderna (NasdaqGS:MRNA) has reached a global settlement with Genevant Sciences and Arbutus Biopharma over lipid nanoparticle ...

FORT LAUDERDALE, FL / ACCESSWIRE / December 2, 2024 / Sunshine Biopharma Inc. (NASDAQ:"SBFM") (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of ...

COMBRIAX is the world's first flu plus COVID combination vaccine to receive a positive CHMP opinion recommending ...

On Friday, the European Commission approved Moderna, Inc.’s (NASDAQ:MRNA) mRESVIA (mRNA-1345), an mRNA respiratory syncytial virus (RSV) vaccine, to protect adults aged 60 years and older from lower ...

Add Yahoo as a preferred source to see more of our stories on Google. National Institutes of Health (NIH) Director Jay Bhattacharya claims the federal government recently canceled millions of dollars’ ...

In August last year, the Health Department cut around $500 million in mRNA research funding, with Health Secretary Robert F.

From global vaccines to personalized cancer therapies, mRNA is being considered across several clinical applications, which ultimately creates varying requirements in terms of production scale and ...

Learn from the MHRA about evolving CMC expectations, submission criteria, and initiatives for streamlining approval routes for mRNA platforms. Continuous processing: Optimizing efficiency & ...

We recently compiled a list of the 10 Most Promising Biotech Stocks According to Hedge Funds. In this article, we are going to take a look at where Moderna, Inc. (NASDAQ:MRNA) stands against the other ...